News Focus
News Focus
Followers 843
Posts 122807
Boards Moderated 10
Alias Born 09/05/2002

Re: mskatiescarletohara post# 1430

Sunday, 01/30/2005 6:33:11 PM

Sunday, January 30, 2005 6:33:11 PM

Post# of 347009
>>VEGF also is the target of a Phase III macular degeneration product, Lucentis (ranibizumab), from South San Francisco-based Genentech Inc., but the Angiosyn compound works through a different pathway.<<

Too bad they aren’t saying what that other pathway is. “Competitive reasons,” no doubt.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”